# Tempus AI, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Tempus AI, Inc.). ## Overview Tempus AI, Inc. is a U.S.-based healthcare technology company that combines diagnostic testing with data and software products for clinical and research use. Its business centers on genomics testing, de-identified data licensing, clinical trial matching, and AI-enabled applications built around a large clinical and molecular dataset. ## Products & services • Oncology and hereditary genomics testing • De-identified data licensing for life sciences • AI-enabled clinical trial matching • Clinical decision support and AI applications • Algorithmic diagnostics (Algos) • Platform services for physicians and researchers - **Genomics / Diagnostics** (75%) — Laboratory testing services including oncology, PCR profiling, hereditary cancer risk, and rare-disease profiling. - **Data and Services** (25%) — De-identified data licensing, analytical services, and clinical trial matching for biopharma customers. - **AI Applications / Next** (0%) — AI-driven applications that route patients to therapy options and support clinical and research workflows. - Oncology and hereditary genomics testing - De-identified data licensing for life sciences - AI-enabled clinical trial matching - Clinical decision support and AI applications - Algorithmic diagnostics (Algos) - Platform services for physicians and researchers ## Customers Tempus sells primarily to healthcare providers and life sciences companies. Physicians, hospitals, genetic counselors, academic centers, and research institutions buy testing and clinical tools, while pharmaceutical and biotechnology companies buy data, trial-matching, and analytical services to support drug development and research. - **Healthcare providers** (primary) — Physicians, hospital systems, and genetic counselors buy genomics tests and clinical tools to support diagnosis and treatment decisions. - **Pharmaceutical companies** (primary) — Drug makers license de-identified data and use trial-matching services to improve research, development, and patient recruitment. - **Biotechnology companies** (secondary) — Biotech customers buy data, analytics, and matching services to support discovery and clinical development programs. - **Academic and research institutions** (secondary) — Universities and research centers use testing and datasets for translational research and clinical studies. - Oncologists and hospital systems order diagnostic testing - Genetic counselors buy hereditary testing for patient screening - Pharmaceutical companies license data and trial-matching services - Biotech firms use datasets and analytics for R&D programs - Academic and research institutions use testing and data tools - Large pharma customers use the platform for clinical trial recruitment ## Geography Tempus is primarily a North American business, with the majority of revenue generated in North America. The company also conducts business in foreign jurisdictions, but the disclosed reporting emphasizes the U.S. base and North American concentration rather than a broad global footprint. - Majority of revenue is generated in North America - U.S. is the core operating and reporting base - Foreign jurisdictions contribute to tax and operating exposure - Geographic concentration ties revenue to U.S. healthcare demand - International reimbursement and regulatory expansion remain relevant ## Strategy Tempus focuses on expanding adoption across both product lines by increasing use among existing customers and adding new ones. Its strategy is to deepen the value of its data platform, launch additional AI-enabled products, and use network effects between diagnostics and data to strengthen customer retention and product performance. - **Increase adoption across existing customers** (short-term) — Higher utilization and upsell activity improve monetization of the installed base and strengthen retention. - **Launch and commercialize new AI products** (medium-term) — New applications extend the platform and create additional monetization paths from the same underlying data asset. - **Deepen network effects from data accumulation** (long-term) — More clinical and molecular data can improve test performance and make the platform more valuable to researchers and clinicians. - Expand adoption within existing healthcare and life sciences accounts - Grow the de-identified data business through renewals and upsells - Launch new AI applications and algorithmic diagnostics - Use network effects from more data to improve product performance - Broaden physician and provider network to increase dataset value - Scale clinical trial matching and research workflows for pharma ## Risks Tempus depends on continued access to de-identified patient data, customer renewals, and successful commercialization of AI and diagnostic products. It also faces competition from established diagnostics, data, and clinical research providers, while reimbursement, regulatory, privacy, and AI-related risks can affect adoption and monetization. - **Customer renewal and contract concentration risk** [high] — Data and services revenue depends on renewals and expansion of existing agreements, and a few customers can represent a meaningful share of revenue. - **Dependence on de-identified patient data** [high] — The platform’s value and monetization depend on continued access to large datasets and the ability to use them commercially. - **AI model and data governance risk** [high] — AI products can create liability or reputational harm if outputs are inaccurate, biased, or based on improperly used data. - **Reimbursement and payer coverage risk** [high] — Diagnostics adoption depends on coverage and reimbursement decisions by commercial and government payers. - **Competitive pressure from established providers** [medium] — Competitors may have greater resources, broader sales forces, or alternative diagnostic technologies. - Customer renewals and contract scope changes can reduce data revenue - Dependence on de-identified patient data creates privacy and access risk - AI products face accuracy, bias, IP, and data provenance risks - Diagnostics depend on payer reimbursement and clinical adoption - Competition includes larger diagnostics and clinical research firms - Large customer concentration can make quarterly results volatile ## Accounting Tempus’s revenue recognition depends on the mix between lab testing, data licenses, and services, which may be recognized at different points in time or over contract terms. Investors should also watch estimates around business combinations, deferred tax valuation allowances, debt-related items, and the timing of revenue in data contracts that can be back-weighted toward later periods. - **Revenue recognition by product line** — Mix shifts can change reported growth and margins - **Seasonality in data revenue** — Quarterly results may be uneven and not directly comparable - **Business combinations** — Can materially affect assets, expenses, and future impairment charges - **Deferred tax valuation allowance** — Affects reported tax benefit and effective tax rate - **Debt and convertible note accounting** — Can create volatility in non-operating results - Diagnostics, data licensing, and services may have different revenue timing - Data contracts can be term-based and subject to renewal assumptions - Back-weighted data revenue can create seasonal quarterly swings - Business combinations can create goodwill and intangible asset estimates - Deferred tax valuation allowance affects reported tax benefit or expense - Debt and convertible note accounting can affect interest and gains/losses --- *Last updated: 2026-04-29T05:03:18.210804+00:00*